In the progression of non-alcoholic steatohepatitis (NASH), NASH-related hepatocellular carcinoma (HCC), and liver cancer, NIK and JAK2/STAT5 signaling in the liver play a significant role. Here, MAP3K14 is linked to metabolic dysfunction-associated steatohepatitis.